SeraCare Introduces New AccuSpan™ Molecular Linearity Panels

MILFORD, Mass., Nov. 4, 2014 /PRNewswire/ -- SeraCare Life Sciences, a provider of high quality biological materials that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, today announced seven new AccuSpan™ molecular linearity panels for the detection of Adenovirus (ADV), Varicella Zoster Virus (VZV), JC Virus (JCV), Herpes Simplex Virus 1 (HSV1), Herpes Simplex Virus 2 (HSV2), Epstein Barr Virus (EBV), and BK Virus (BKV).

These new linearity panels from SeraCare help assay developers thoroughly challenge their transplant assays from extraction phase through amplification. Each panel consists of four members: one negative, one low positive, one medium positive, and one high positive sample. These panels are provided in a ready-to-go single-use format with target concentrations that cover the dynamic range of most molecular assays and are consistent within each lot and across batches.

"We are excited to introduce these new viral linearity panels and provide customers with a single source for their assay validation needs," said Christopher Long, Product Manager at SeraCare Life Sciences. "Our new panels can be used to challenge the assay, ensuring that it's validated, running properly and recording the correct results. They are an essential tool for critical viral monitoring and part of a complete lab QC program."

Visit SeraCare booth #1119 at AMP in National Harbor, MD November 13-15 to learn more about these new products. SeraCare's new AccuSpan™ Linearity panels will be available for purchase by November 30, 2014. For more information, contact SeraCare Customer Service at 1-800-676-1881 or visit www.seracare.com.

About SeraCare Life Sciences, Inc.
SeraCare partners with diagnostics researchers, IVD manufacturers and clinical laboratories to shape the future of precision medicine. Our innovative portfolio includes ACCURUN^® quality controls, research panels, SeraCon^® processed biological materials, specialty human blood products and characterized disease state materials. SeraCare helps bridge the gap between today's diagnostic solutions and tomorrow's emerging technologies for molecular diagnostics, next generation sequencing and companion diagnostics. For more information, visit www.seracare.com.

Photo - http://photos.prnewswire.com/prnh/20141103/156267

SOURCE SeraCare Life Sciences, Inc.

Related Links

http://www.seracare.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED